<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04840238</url>
  </required_header>
  <id_info>
    <org_study_id>PAT15-PCODD</org_study_id>
    <nct_id>NCT04840238</nct_id>
  </id_info>
  <brief_title>30000 IU Per Week Vitamin D Treatment in PCOS Patients</brief_title>
  <official_title>A Multicentre, Phase-II, Randomised, Double Blind, Placebo-controlled Study to Assess the Safety and the Efficacy of a Weekly Administered Dose of 30,000 IU Vitamin D (Colecalciferol) in Deficient Patients Diagnosed With PCOS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Semmelweis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharma Patent Kft.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Semmelweis University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a human, II/b phase, multicentre, randomised, double blind, placebo-controlled study&#xD;
      to assess the safety and the efficacy of a weekly administered dose of 30,000 IU vitamin D&#xD;
      (colecalciferol) in deficient patients diagnosed with PCOS.&#xD;
&#xD;
      Investigational products: 30.000 IU vitamin D or placebo administered once a week for&#xD;
      12-weeks-long period, followed by a 12-week-long open label treatment 30.000 IU vitamin D in&#xD;
      a follow-up period.&#xD;
&#xD;
      Each participant should be checked for regular dietary Ca intake and to assure the optimal&#xD;
      calcium level the supplementation is provided with a commercially available Citrocalcium 200&#xD;
      mg tablets.&#xD;
&#xD;
      Setting:&#xD;
&#xD;
      I. Baseline and screening period:&#xD;
&#xD;
      Baseline period considered as when the exogenous Vitamin D intake should not exceed the level&#xD;
      of 1000 IU intake per day or a total 5000 NE per week dosages applied (in forms of any&#xD;
      Vitamin D3 medication or multivitamin products) at least for 30 days prior the assessment&#xD;
      made.&#xD;
&#xD;
      II. Double-blind treatment period:&#xD;
&#xD;
      Once a week per os applied Vitamin D or placebo treatment for 12 weeks according to&#xD;
      randomisation of trial subjects in a 1:1 assignment. By the end of this period an interim&#xD;
      assessment will be performed based on the analysis of primary efficacy parameters,&#xD;
      stratification to responder and non-responder groups.&#xD;
&#xD;
      III. Open label and follow-up phase:&#xD;
&#xD;
      An open-label 30000 IU of Vitamin D treatment on weekly basis. (Vitamin D3 Pharma Patent&#xD;
      30000 IU tablets) for additional 12 weeks and continue with the follow-up assessments. A&#xD;
      compassionate use of patient diary for additional 26 weeks.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Primary objectives: to assess the efficacy as a recovery of ovarian function based on&#xD;
      progesterone levels and menses diary in at least 20% of trial subjects, compared to placebo&#xD;
      treated group Secondary Objectives: assess the efficacy and safety of orally administered&#xD;
      vitamin D treatment by the changes in 25(OH) D levels in PCOS patients.&#xD;
&#xD;
      Explore the changes in Ovarian-morphology based on the results of standard TVUS Imaging:&#xD;
      detection of adverse drug reactions during treatment periods, by frequency and distribution&#xD;
      compared to follow-up periods and placebo group.&#xD;
&#xD;
      Anticipated participants: 168&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2016</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery of ovarian function</measure>
    <time_frame>Up to 32 weeks, continuously</time_frame>
    <description>Recovery of ovarian function is detected by changes in progesterone levels (lutal phase progesterone level reaches 2 ng/ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of menstrual cycle</measure>
    <time_frame>Up to 32 weeks</time_frame>
    <description>Determined by patient reported number of days between two menstrual cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in menstrual cycles length</measure>
    <time_frame>Up to 32 weeks</time_frame>
    <description>Determined by patient reported menstrual cycle length and regularity, measured in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 32 weeks, continuously</time_frame>
    <description>Incidence of adverse events (safety and tolerability), evaluated at every visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum calcium level</measure>
    <time_frame>Up to 32 weeks, continuously</time_frame>
    <description>Change in serum calcium levels in mmol/l (safety measure), evaluated every clinical visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary calcium/creatinine ratio</measure>
    <time_frame>Up to 32 weeks</time_frame>
    <description>Change in urinary calcium/creatinine ratio ([mmol/l]/[umol/l]) (safety measure), evaluated every clinical visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25(OH)D levels</measure>
    <time_frame>Up to 32 weeks</time_frame>
    <description>Evaluation of treatment of changes in 25(OH)D blood levels compared between treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting glucose level</measure>
    <time_frame>Up to 32 weeks</time_frame>
    <description>Change in fasting glucose level (mmol/l), measured at every visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin A1c level</measure>
    <time_frame>Up to 32 weeks</time_frame>
    <description>Change in hemoglobin A1c level (IFCC validated, mmol/mol), measured every 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ovarian morphology</measure>
    <time_frame>Up to 32 weeks</time_frame>
    <description>Changes in ovarian follicle count assessed by TVUS and evaluated by the Rotterdam criteria (having 12 or more follicles, measuring between 2 and 9 mm)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cholecalciferol 30,000IU weekly orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets weekly orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>30,000IU cholecalciferol</description>
    <arm_group_label>Cholecalciferol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female subject age &gt;18 years.&#xD;
&#xD;
          -  Clinical and/or biochemical hyperandrogenism and the proven PCOS by the &quot;Rotterdam&quot;&#xD;
             criteria, (ovarian dysfunction, oligo- and/or anovulation, and the morphology of&#xD;
             polycystic ovaries on ultrasound images when other etiologies are excluded)&#xD;
&#xD;
          -  25(OH)D levels are between 10-28 ng/ml by inclusion&#xD;
&#xD;
          -  Subject can not be under any kind of ongoing hormone or metformin therapies and no&#xD;
             indication that requires continuation&#xD;
&#xD;
          -  Has the ability and willingness to understand and comply with study procedures and to&#xD;
             give written informed consent prior to enrollment in the study or initiation of study&#xD;
             procedures&#xD;
&#xD;
          -  Study subject has the ability and willingness to understand and comply with study&#xD;
             procedures and to give written informed consent prior to enrollment in the study or&#xD;
             initiation of study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has been exposed to any investigational agent within 3 month of enrolment to the study&#xD;
&#xD;
          -  Sever metabolic disease on endocrine disease in etiology different from PCOS&#xD;
&#xD;
          -  Significant obesity (BMI&gt; 36)&#xD;
&#xD;
          -  Any other signs of lab results that may lead to other etiologies in differentiation,&#xD;
             or menopause&#xD;
&#xD;
          -  Increased serum calcium level results or symptoms of hypercalcemia in last one year&#xD;
&#xD;
          -  Hypercalciuria or kidney stone appearance in last one year&#xD;
&#xD;
          -  Sever kidney diseases (CKD 3 or higher)&#xD;
&#xD;
          -  Chronic or serious disease, which can significantly influence the absorption,&#xD;
             metabolism of vitamin D or Ca&#xD;
&#xD;
          -  Heart failure or angina pectoris,&#xD;
&#xD;
          -  More than 1000 IU vitamin D per day intake or in total &gt;5000 IU per week within 1&#xD;
             month prior to trial (in any forms medication, or nutritional food supplement). The&#xD;
             patient is not under hormonal therapy for ovulation stimulation purposes and was not&#xD;
             involved in two months prior the study&#xD;
&#xD;
          -  The patient is under hormonal therapy for the aim of ovulation stimulation or was&#xD;
             involved in within 3 months prior the study&#xD;
&#xD;
          -  Existence or suspected gravidity&#xD;
&#xD;
          -  Any other finding or symptoms which are by the opinion of the Investigator may&#xD;
             indicate a potential interference with the safety of participating trial subjects&#xD;
&#xD;
          -  Has a known hypersensitivity to any of the investigational drug or vehicle components.&#xD;
&#xD;
          -  Concomitant medication which is not allowed:&#xD;
&#xD;
               -  glycosides&#xD;
&#xD;
               -  metformin&#xD;
&#xD;
               -  magnesium-containing preparations (antacids)&#xD;
&#xD;
               -  cholestyramine and other ion exchange resins, orlistat&#xD;
&#xD;
               -  thiazide diuretics&#xD;
&#xD;
               -  regular use of microsomal enzyme inducers (anticonvulsants, sedatives, etc.).&#xD;
&#xD;
               -  corticosteroids (except for dermatological use)&#xD;
&#xD;
               -  products containing phosphorus&#xD;
&#xD;
               -  regular use of laxatives (such as paraffin oil)&#xD;
&#xD;
               -  fat absorption inhibitory drugs&#xD;
&#xD;
               -  any kind of hormone therapy (including therapeutic use of birth control pills,&#xD;
                  within 2 months prior inclusion) except treatment of stabile hypothyroidism&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Polycystic ovarian syndrome develops in only females</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>István Takács, MD, DSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Semmelweis University - Dept. of Medicine and Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pál Szamosújvári, MD</last_name>
    <phone>+36 1 630 61 82</phone>
    <email>clinical@pharmapatent.hu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>István Takács, MD, DSc.</last_name>
    <phone>+36 210 0278</phone>
    <phone_ext>51526</phone_ext>
    <email>takacs.istvan@med.semmelweis-univ.hu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Semmelweis University - Departement Medicine and Oncology</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Lakatos, MD, DSc.</last_name>
      <phone>+36-1-210-0278</phone>
      <phone_ext>51526</phone_ext>
      <email>lakatos.peter@med.semmelweis-univ.hu</email>
    </contact>
    <contact_backup>
      <last_name>Balazs Szili, MD</last_name>
      <phone>+36-1-210-0278</phone>
      <phone_ext>51526</phone_ext>
      <email>szili.balazs@med.semmelweis-univ.hu</email>
    </contact_backup>
    <investigator>
      <last_name>Istvan Takacs, MD, DSc.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Balazs Szili, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bence Bakos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MediMOM Healthy Center</name>
      <address>
        <city>Budapest</city>
        <zip>1112</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sándor Hamar, MD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Róbert Károly Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>1136</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pál Siklós, MD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gynpraxis Nőgyógyászat</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Attila Jakab, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Somogy County Kaposi Mór Teaching Hospital</name>
      <address>
        <city>Kaposvár</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enikő Dezső, MD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Borsod-Abaúj-Zemplén County Hospital</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imre Molnár, MD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SZTE-ÁOK - 1st Dept. of Internal MEdicine</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zsuzsanna Valkusz, MD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gynofarm Outpatient Clinic</name>
      <address>
        <city>Székesfehérvár</city>
        <zip>8600</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Levente Rubliczky, MD.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Semmelweis University</investigator_affiliation>
    <investigator_full_name>Istvan Takacs</investigator_full_name>
    <investigator_title>M.D., DSc., Director of Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

